Building Resiliency in Dyads of Patients With an ANI Admitted to the Neuro-ICU and Their Informal Caregivers
Launched by MASSACHUSETTS GENERAL HOSPITAL · Dec 1, 2021
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to help patients with acute brain injuries and their caregivers by testing a program that aims to reduce emotional distress. The study involves a series of six sessions where both the patient and their caregiver participate together. The goal is to support these "dyads" (the patient and caregiver) during their stay in the Neuro-Intensive Care Unit (NICU) and help them cope better, which may lead to improved recovery and a better overall quality of life.
To take part in this trial, participants should be at least 18 years old, speak and read English, and have a caregiver who is willing to join. Patients must be currently hospitalized for an acute neurological injury (like a stroke or severe head injury) and show signs of emotional distress. However, individuals with certain conditions, like severe cognitive impairments or untreated mental health issues, may not be eligible. If you or a loved one is interested in participating, you can expect to engage in supportive sessions that focus on building resilience and coping strategies during a challenging time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 or older
- • English fluency and literacy
- • Patient with an informal caregiver available and willing to participate
- • Hospitalized with any ANI within 6 weeks (patient) OR informal caregiver of a patient currently admitted with any ANI
- • Patient and/or caregiver exhibit emotional distress on screening (using HADS D and/or HADS A scores \> 7)
- Exclusion Criteria:
- • Permanent cognitive impairment (including severe hearing impairment) or aphasia that makes participation impossible
- • Short form of Mini-Mental State Exam (SMMSE) score \<4 (If SMMSE \<4, nursing team decides whether or not the patient can meaningfully participate)
- • Glasgow Coma Scale (GCS) score \<10
- • Terminal diagnosis
- • Lack of access to internet and/or a device with a camera
- • Current untreated or unstable severe mental health conditions like bipolar disorder, schizophrenia, or active substance use
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials